Wells Fargo & Company Replimune Group, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REPL
# of Institutions
156Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$121 Million1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.24MShares$111 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$66.9 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$58.5 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$56.7 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $593M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...